Drug Database · Clinicians

Lidocaine

Also known as: lignocaine (former British name)

Brands (27) Eurocaine, Lidosur, Lignovell…Show all

US brand (reference label): XYLOCAINE MPF; not a Philippine-registered brand.

Local anesthetic (amide); Local Anesthetic/Antiarrhythmic; and others PH FDA category

Rx · Prescription drug35 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 1986c302-82a0-95a9-e063-6294a90a3339, version date September 2, 2026 (XYLOCAINE MPF · HF Acquisition Co LLC, DBA HealthFirst). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block…
US FDA label
Full indications and usage US FDA label

Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

Contraindications

Lidocaine HCl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Xylocaine Injection for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated.

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Xylocaine is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION). These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures.

The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given.

Dosages should be reduced for children and for the elderly and debilitated patients and patients with cardiac and/or liver disease. The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Thus, an increase in volume and concentration of Xylocaine Injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia.

However, increasing the volume and concentration of Xylocaine Injection may result in a more profound fall in blood pressure when used in epidural anesthesia. Although the incidence of side effects with lidocaine HCl is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.

For intravenous regional anesthesia, only the 50 mL single dose vial containing Xylocaine (lidocaine HCl) 0.5% Injection should be used. Epidural Anesthesia For epidural anesthesia, only the following dosage forms of Xylocaine Injection are recommended: 1% without epinephrine 10 mL Plastic Ampule 1% without epinephrine 30 mL single dose solutions 1% with epinephrine 1:200,000 30 mL single dose solutions 1.5% without epinephrine 10 mL Plastic Ampule 1.5% without epinephrine 20 mL Plastic Ampule 1.5% with epinephrine 1:200,000 30 mL ampules, 30 mL single dose solutions 2% without epinephrine 10 mL Plastic Ampule 2% with epinephrine 1:200,000 20 mL ampules, 20 mL single dose solutions Although these solutions are intended specifically for epidural anesthesia, they may also be used for infiltration and peripheral nerve block, provided they are employed as single dose units.

These solutions contain no bacteriostatic agent. In epidural anesthesia, the dosage varies with the number of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome). Caudal and Lumbar Epidural Block As a precaution against the adverse experience sometimes observed following unintentional penetration of the subarachnoid space, a test dose such as 2 to 3 mL of 1.5% lidocaine HCl should be administered at least 5 minutes prior to injecting the total volume required for a lumbar or caudal epidural block.

The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose (10 to 15 mcg have been suggested), may serve as a warning of unintentional intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient “epinephrine response” within 45 seconds, consisting of an increase in heart rate and systolic blood pressure, circumoral pallor, palpitations and nervousness in the unsedated patient.

The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Patients on beta blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure. Adequate time should be allowed for onset of anesthesia after administration of each test dose.

The rapid injection of a large volume of Xylocaine Injection through the catheter should be avoided, and, when feasible, fractional doses should be administered. In the event of the known injection of a large volume of local anesthetic solution into the subarachnoid space, after suitable resuscitation and if the catheter is in place, consider attempting the recovery of drug by draining a moderate amount of cerebrospinal fluid (such as 10 mL) through the epidural catheter.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Solution for injection: 20 mg/mL, 400 mg/20 mL
  • Per actuation topical spray: 10 mg/0.1 mL
  • ) solution for injection: 20 mg/mL
  • Solution for intravenous injection: 20 mg/mL
  • Spray: 10 mg/dose
  • W/v) solution for injection: 10 mg/mL (1 %

Registered products in the Philippines

35 products registered with the Food and Drug Administration (FDA) Philippines list Lidocaine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Lidocaine Injection (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products35
Philippine FDA-registered products for Lidocaine
Package insert
AnestinLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection (IM/IV)50 mL Type III Clear Glass Vial x 1's (Box of 10's)
Rx
SYNCOM FORMULATIONS (INDIA) LTD.India
ARVINCARE PHARMA INC.
DRP-2820
Feb 25, 2028
BlesanumbLidocaine Hydrochloride
10 mg/mL (1%w/v) Solution For Injection (IM/IV)5 mL USP Type I clear glass ampoule (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Afree Pharmaceutical Distribution Corp.
DRP-13052
Nov 23, 2027
DocileLidocaine InjectionVariant spelling
20 mg/mL (2% w/v) Solution for Intravenous (IV) InjectionUSP Type I Glass Vial x 20 mL (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Applied Pharmaceutical Distribution Inc.
DRP-12677
Sep 22, 2027
Endo-proLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection (I.M.I.V.)USP Type I clear and colorless glass vial x 50 mL (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DR-XY46991
Aug 6, 2030
EurocaineLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection (IV/IM)USP Type II Glass Vial with Rubber Stopper and Blue Flip-off Seal x 50 mL (Box of 20's)
Rx
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY-49636
Feb 11, 2031
EurocaineLidocaine Hydrochloride (as monohydrate)
20 mg/mL (2% w/v) Solution for Injection (IV/IM)5 mL Low Density Polyethylene (LDPE) ampoule x 5's (box of 50's)
Rx
Euro-Med Laboratories Phil., IncPhilippines
—
DR-XY37158
Dec 3, 2029
EurocaineLidocaine Hydrochloride (as Monohydrate)
20 mg/mL (2% w/v) Solution for Injection (IV/IM)LDPE Vial x 20 mL and 50 mL
Rx
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY40132
Oct 5, 2031
InocaineLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection (I.M./S.C.)Type I clear glass vials with 20 mm grey silicone rubber closure and 20 mm blue flip off seal x 10 mL (Box of 10's)
Rx
Pharmaniaga Lifesciences Sdn. Bhd.Malaysia
Endure Medical, Inc.
DR-XY49138
Jul 31, 2029
LidoLidocaine (as Hydrochloride)
20 mg/mL (2%) Solution for InjectionType I Amber Coloured Glass Vial x 50 mL (Box of 1's)
Rx
Kwality Pharmaceuticals Ltd.India
Janamed Corporation
DR-XY40379
Dec 7, 2031
LidochemLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution For Injection (I.V.)Type I Clear Glass ampoule x 5 mL (Box of 10's)
Rx
Pharmax India Pvt. Ltd.India
Wellchem Pharmaceutical Products
DRP-18790
Sep 8, 2031
LidomedLidocaine Hydrochloride (As Monohydrate)
20mg/mL (2% w/v) Solution For Injection (IM/IV)Type-I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with White PP Flip Off Cap x 20 mL (Box of 1's)
Rx
Skymap Healthcare Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-18159
May 19, 2032
LidonemLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection (I.V.)Polypropylene ampoule x 5 mL, 10 mL, and 20 mL (Box of 10's, 30's, and 50's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-15139
May 29, 2029
LidooneLidocaine Hydrochloride
10 mg/0.1 mL per actuation (10% w/v) Topical SprayType III clear and colorless glass vial with white pump sprayer and cap × 50 mL (Box of 1’s)
Rx
Royale Life Pharma Inc.Philippines
—
DRP-18595
Aug 3, 2031
LidophilLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution For Injection (IV)20 mL and 50 mL USP Type I clear colorless glass vial with grey bromobutyl rubber stopper, aluminum seal and blue ip-off cap (Box of 1's and 50's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-12934
Nov 4, 2027
LidosaphLidocaine Hydrochloride
20mg/ml (2% w/v) Solution For Injection (IV)LDPE ampoule x 5 mL (box of 50's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-14078
Jun 15, 2028
LidosurLidocaine Hydrochloride
10% w/v Topical Spray50 mL glass bottle with spray nozzle (Box of 1's)
Rx
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International, Inc.
DRP-18227
Jun 2, 2031
LidosurLidocaine hydrochloride
20 mg/mL (2%) Solution for Injection (IM/IV)Type I clear glass vial with grey bromobutyl rubber stopper and orange-colored aluminum flip-off seal x 20 mL (Box of 1’s, 10’s and 25’s); Type I clear glass vial with grey bromobutyl rubber stopper and orange-colored aluminum flip-off seal x 50 mL (Box of 1’s, 10’s and 25’s)
Rx
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International Inc.Trader: N/A
DRP-18050
Apr 30, 2031
LignovellLidocaine (as hydrochloride)
10 mg/dose SprayType I clear glass vials with white opaque PE sprayer with I long nozzle and cap x 50 mL (Box of 1's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY49141
Jul 31, 2029
LignovellLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection (IV)Type I amber glass ampoule x 2 mL (Box of 5's)
Rx
Pt. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY48054
May 26, 2027
LinocaineLidocaine hydrochloride
20mg/mL (2% w/v) Solution for Injection (IM/IV)Type I Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Flip Cap x 10 mL (Box of 10's)
Rx
SM Pharmaceuticals Sdn. Bhd.Malaysia
Phil. Pharmawealth, Inc.
DR-XY49307
Jan 7, 2030
LitaineLidocaine Hydrochloride
400 mg/20 mL Solution for Injection20 ml USP type ii glass vial with grey Chlorobutyl stopper with aluminum fittings with flip-off cap (Box of 1's)
Rx
Dai Han Pharm. Co. Ltd.Republic of Korea
Bellus Life Solutions, Inc.
DRP-13725
Mar 31, 2031
LocaineLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for Injection50 mL USP Type I Amber-colored Vial with Gray Butyl Rubber Plug and Blue Flip-off Aluminum Seal (Box of 1's)
Rx
Shreechem Pharmaceuticals Pvt., Ltd.India
Aglobal Care, Inc.
DR-XY43264
Feb 26, 2029
LydosolvLidocaine hydrochloride (as monohydrate)
20 mg/mL (2% w/v) Solution for Injection (IV)Type I Amber Colored Glass Vial with Grey Bromobutyl Rubber Stopper and Plastic Red Lacquered Flip-Off Cap x 20 mL (Box of l's)
Rx
Indoco Remedies LimitedIndia
Ambica International Corporation
DRP-10858
Dec 9, 2026
NoneLidocaine Hydrochloride
20 mg/mL (2% w/v) Solution for InjectionLDPE Vial with Rubber Stopper x 20 mL (Box of 20's)
Rx
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY 25885
Feb 1, 2030
NoneLidocaine Hydrochloride (as monohydrate)
20 mg/mL (2%) Solution for Injection5 mL Low Density Polyethylene Ampoule (Box of 50's)
Rx
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY 34236
Jan 31, 2028
PuriecaineLidocaine Hydrochloride (as monohydrate)
20 mg/mL (2%) Solution For InjectionUSP Type I Clear Glass Ampoule x 5 mL (Box of 5 ampoules in plastic tray)
Rx
Makcur Laboratories LimitedIndia
Diafarm Inc.
DRP-14838
Jan 23, 2029
RoyalecaineLidocaine hydrochloride
20mg/mL (2% w/v) Solution For InjectionUSP Type I Clear and Colorless glass vial with gray bromobutyl rubber stopper and aluminu, crimp seal with red plastic cap x 5 mL, 10 mL, 20 mL and 50 mL (Box of 1's)
Rx
Royale Life Pharma Inc.Philippines
Importer: N/A
DRP-18596
Sep 1, 2031
SaphdocaineLidocaine Hydrochloride
20mg/mL (2% w/v) Solution for Injection (I.V.)Low Density Polyethylene (LDPE) Ampoule with Protective Cap x 5 mL (Box of 50's)
Rx
Althea Pharma Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12663
Sep 20, 2027
Saphdocaine-2%Lidocaine Hydrochloride
20mg/mL (2% w/v) Solution For InjectionType 1 Flint Amber Glass Vial with Gray Bromobutyl Rubber Stopper and Light Blue Aluminum Flip-Off Seal Cap x 20 mL (Box of 1's)
Rx
Althea Pharma Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13938
May 19, 2028
Saphdocaine-B20Lidocaine hydrochloride
20mg/mL (2% w/v) Solution for Injection (IV)Type I Amber Glass Vial x 20mL and 50mL (Box 1’s)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-18769
Sep 3, 2031
SenziteneLidocaine (as Hydrochloride)
20 mg/mL (2%) Solution for Injection (I.M./I.V)5 mL Type I Clear and Colorless Glass Ampoule (Box of 10’s)
Rx
Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY45484
Jul 1, 2031
UnbrandedLidocaine Hydrochloride
2% (20mg/mL) Solution for Injection (Epidural, Local Infiltration)USP Type II Glass Amber Vial x 10mL and 50mL NA
Rx
EL Laboratories, Inc.Philippines
Trader: Elin Pharmaceuticals, Inc.
DR-XY1229
May 24, 2031
XylocaineLidocaine
10mg/0.1 mL per actuation (10% w/v) Topical SprayType I colorless glass vial fitted with dose valve and plastic spray nozzle applicator x 50 mL (Box of 1’s)
Rx
Aspen Bad Oldesloe GmbHGermany
N/AImporter: Aspen Philippines, Inc.Trader: Aspen Global Incorporated
DR-XY48561
Jan 9, 2028
XylocaineLidocaine Hydrochloride
20 mg/mL (2%) Solution for InjectionPolyamp Duofit x 5 mL Box of 50's
Rx
AstraZeneca Pty. Ltd.Australia
Aspen Philippines, Inc.
DR-XY15681
Nov 12, 2029
XylocareLidocaine Hydrochloride
20 mg/mL (2%) Solution for Injection (I.M./I.V.)50 mL USP Type II Clear Colorless Glass Vial (Box of 1's)
Rx
Vesco Pharmaceutical Company LimitedThailand
Euro-Care Products Philippines
DR-XY42119
Jun 14, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

XYLOCAINE INJECTIONS FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and PRECAUTIONS). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.

Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition.

If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death.

Discontinue Xylocaine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions.

The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings.

The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.

To avoid intravascular injection, aspiration should be performed before the local anesthetic solution is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.

Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental. Xylocaine with epinephrine solutions contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. Anaphylactic reactions may occur following administration of lidocaine hydrochloride (see ADVERSE REACTIONS). In the case of severe reaction, discontinue the use of the drug.

Adverse reactions

Adverse reactions (US label) US FDA label

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Systemic Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.

Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: Central Nervous System CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest.

The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of lidocaine HCl is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

Cardiovascular System Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest. Allergic Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials.

Allergic reactions, including anaphylactic reactions, may occur as a result of sensitivity to lidocaine, but are infrequent. If allergic reactions do occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine.

Neurologic The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient. In a prospective review of 10,440 patients who received lidocaine HCl for spinal anesthesia, the incidences of adverse reactions were reported to be about 3 percent each for positional headaches, hypotension and backache; 2 percent for shivering; and less than 1 percent each for peripheral nerve symptoms, nausea, respiratory inadequacy and double vision.

Many of these observations may be related to local anesthetic techniques, with or without a contribution from the local anesthetic. In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter may occur. Subsequent adverse effects may depend partially on the amount of drug administered subdurally.

These may include spinal block of varying magnitude (including total spinal block), hypotension secondary to spinal block, loss of bladder and bowel control, and loss of perineal sensation and sexual function. Persistent motor, sensory and/or autonomic (sphincter control) deficit of some lower spinal segments with slow recovery (several months) or incomplete recovery have been reported in rare instances when caudal or lumbar epidural block has been attempted.

Backache and headache have also been noted following use of these anesthetic procedures. There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration. Hematologic Methemoglobinemia.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Lidocaine HCl is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys.

Approximately 90% of lidocaine HCl administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged.

The elimination half-life of lidocaine HCl following an intravenous bolus injection is typically 1.5 to 2 hours.

The half-life may be prolonged two-fold or more in patients with liver dysfunction.

Pharmacokinetics (US label) US FDA label

Mechanism of Action Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Hemodynamics Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure.

With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present. The net effect is normally a modest hypotension when the recommended dosages are not exceeded.

Pharmacokinetics and Metabolism Information derived from diverse formulations, concentrations and usages reveals that lidocaine HCl is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.

The plasma binding of lidocaine HCl is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL 60 to 80 percent of lidocaine HCl is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

Lidocaine HCl crosses the blood-brain and placental barriers, presumably by passive diffusion. Lidocaine HCl is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.

N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine HCl. Approximately 90% of lidocaine HCl administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged.

The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The elimination half-life of lidocaine HCl following an intravenous bolus injection is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine HCl is metabolized, any condition that affects liver function may alter lidocaine HCl kinetics.

The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine HCl kinetics but may increase the accumulation of metabolites. Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine HCl required to produce overt systemic effects.

Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL. In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Lidocaine 2%, 1.8mL w/ epinephrine Carpule₱18.20–₱29.00Reference ₱18.20per unitDPRI procurement range
Lidocaine 2%, 20 mL Ampule₱7.68–₱12.00Reference ₱7.68per ampuleDPRI procurement range
Lidocaine 2%, 5 mL Ampule₱6.74–₱36.63Reference ₱10.00per ampuleDPRI procurement range
Lidocaine 2%, 5 mL Vial₱10.24–₱11.94Reference ₱10.24per vialDPRI procurement range
Lidocaine 2%, 50 mL Vial₱14.74–₱55.00Reference ₱36.91per vialDPRI procurement range
Lidocaine 10%, 50 mL Spray₱1,993.91–₱2,707.75Reference ₱1,993.91per unitDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Lidocaine (as hydrochloride)
PNF listingInj.: 1%, 20 mL ampulRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 2% (20 mg/mL), 2 mL, 5 mL, 20 mL and 50 mL ampul/vial (IM/IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 2%, 5 mL and 50 mL vial (epidural, local infiltration)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 2%, 1.8 mL carpule (with epinephrine) (local infiltration) Spray: 10%, 50 mLRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. XYLOCAINE MPF · HF Acquisition Co LLC, DBA HealthFirst [US FDA-approved label, version 4, September 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1986c302-82a0-95a9-e063-6294a90a3339
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .